📊 COYA Key Takeaways
Is Coya Therapeutics, Inc. (COYA) a Good Investment?
Coya Therapeutics is a pre-commercial biotech company burning $6.2M annually while generating only $251K in revenue, indicating it is in early development stages with uncertain commercialization prospects. While the strong cash position ($50.7M) and zero debt provide operational runway (~8 years at current burn), the lack of revenue traction, flat year-over-year net losses, and deteriorating EPS (-29.6% YoY) suggest execution challenges and elevated risk of shareholder dilution through future capital raises.
Coya Therapeutics shows strong balance-sheet quality for a clinical-stage biotech, with $46.82M of cash, no meaningful debt, and very high liquidity. Revenue growth was sharp, but profitability remains deeply negative, with operating margin of -283.9% and free cash flow of -$10.74M, indicating the business is still heavily dependent on external funding or future commercialization success. Fundamentally, this is a financially stable but still highly speculative company where cash runway and the durability of revenue growth matter more than current earnings.
Coya Therapeutics, Inc. Key Strengths (COYA)
- Substantial cash position of $50.7M (95% of total assets) provides multi-year operational runway
- Zero debt with clean balance sheet (0.00x debt-to-equity ratio)
- Strong liquidity metrics (15.02x current ratio) enable extended investment in R&D without near-term bankruptcy risk
- Revenue growth of 123.6% YoY, though from minimal base of $251K
- Very strong liquidity, with 8.50x current and quick ratios supported by $46.82M in cash
- Debt-free balance sheet and modest liabilities relative to $43.03M in equity
- Revenue grew 123.6% YoY, showing improving top-line traction
COYA Stock Risks: Coya Therapeutics, Inc. Investment Risks
- Massive operating losses of $7.6M against revenue of $251K indicate unsustainable unit economics and pre-commercial stage
- Negative free cash flow of $6.2M annually with no clear path to profitability in visible metrics
- Net income flat year-over-year ($0.0% change) suggests no improvement in loss trajectory despite size
- EPS deteriorating at -29.6% YoY indicates worsening per-share performance
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low insider confidence in near-term execution
- Pharmaceutical sector requires successful clinical development and regulatory approval—inherent binary risk of failure
- Extremely weak profitability, with -283.9% operating margin and -267.1% net margin
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Revenue quality may be less durable if driven by partnership or non-recurring sources rather than broad commercial operations
Key Metrics to Watch
- Operating cash flow trajectory and cash runway calculation
- Revenue growth rate and path to gross margin positivity
- Clinical trial progress, regulatory milestones, and FDA interactions
- Operating expense burn rate reduction or stabilization
- Insider transaction activity and equity dilution from future fundraising rounds
- Quarterly operating cash burn relative to cash balance
- Revenue consistency and progress toward narrower operating losses
Coya Therapeutics, Inc. (COYA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.02x current ratio provides a solid financial cushion.
COYA Profit Margin, ROE & Profitability Analysis
COYA vs Healthcare Sector: How Coya Therapeutics, Inc. Compares
How Coya Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Coya Therapeutics, Inc. Stock Overvalued? COYA Valuation Analysis 2026
Based on fundamental analysis, Coya Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Coya Therapeutics, Inc. Balance Sheet: COYA Debt, Cash & Liquidity
COYA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Coya Therapeutics, Inc.'s revenue has grown significantly by 32% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.98 indicates the company is currently unprofitable.
COYA Revenue Growth, EPS Growth & YoY Performance
COYA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $251.1K | -$7.2M | $-0.32 |
| Q3 2025 | $3.6M | -$2.1M | $-0.13 |
| Q2 2025 | $163.6K | -$2.9M | $-0.19 |
| Q1 2025 | $126.8K | -$5.1M | $-0.35 |
| Q3 2024 | N/A | -$2.7M | $-0.26 |
| Q2 2024 | N/A | -$2.7M | $-0.19 |
| Q1 2024 | N/A | -$2.7M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Coya Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
COYA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Coya Therapeutics, Inc. (CIK: 0001835022)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COYA
What is the AI rating for COYA?
Coya Therapeutics, Inc. (COYA) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COYA's key strengths?
Claude: Substantial cash position of $50.7M (95% of total assets) provides multi-year operational runway. Zero debt with clean balance sheet (0.00x debt-to-equity ratio). ChatGPT: Very strong liquidity, with 8.50x current and quick ratios supported by $46.82M in cash. Debt-free balance sheet and modest liabilities relative to $43.03M in equity.
What are the risks of investing in COYA?
Claude: Massive operating losses of $7.6M against revenue of $251K indicate unsustainable unit economics and pre-commercial stage. Negative free cash flow of $6.2M annually with no clear path to profitability in visible metrics. ChatGPT: Extremely weak profitability, with -283.9% operating margin and -267.1% net margin. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is COYA's revenue and growth?
Coya Therapeutics, Inc. reported revenue of $251.1K.
Does COYA pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
Where can I find COYA SEC filings?
Official SEC filings for Coya Therapeutics, Inc. (CIK: 0001835022) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COYA's EPS?
Coya Therapeutics, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is COYA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Coya Therapeutics, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is COYA stock overvalued or undervalued?
Valuation metrics for COYA: ROE of -14.7% (sector avg: 15%), net margin of -2,869.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is COYA's AI grade for 2026?
Our dual AI analysis gives Coya Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COYA's free cash flow?
Coya Therapeutics, Inc.'s operating cash flow is $-6.2M, with capital expenditures of N/A. FCF margin is -2,472.1%.
How does COYA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,869.6% (avg: 12%), ROE -14.7% (avg: 15%), current ratio 15.02 (avg: 2).